Product Name

Serdemetan

General description

Serdemetan acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

Synonym

JNJ-26854165; 1-N-[2-(1H-indol-3-yl)ethyl]-4-N-pyridin-4-ylbenzene-1,4-diamine

Purity

≥98.0%(HPLC)

CAS Number

881202-45-5

Formula

C₂₁H₂₀N₄

Molecular Weight

328.419

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

Solid

Solubility(25°C)

DMSO

≥50mg/ml

Ethanol

Slightly soluble

Water

Very slightly soluble

l  Biological Information

Biochem/Physiol  Actions

Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often over expressed in cancer cells, it has been implicated in cancer cell proliferation and survival.

l  Storage

Storage temp.

-20°C

l  Precautions and Disclaimer

This product is for R&D use only, not  for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov